Celyad Oncology SA

CYAD

BE0974260896

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 11:55:00 2026-06-11 am EDT			5-day change	1st Jan Change
0.2820 ^EUR	-0.70%		+3.68%	+65.88%

Apr. 15	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
Apr. 02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Celyad Oncology announces research facility divestiture

Published on 09/29/2025 at 01:16 pm EDT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Celyad Oncology SA

Apr. 15	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
Apr. 02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-09-30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
25-09-29	Celyad Oncology announces research facility divestiture	RE
25-09-28	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25-09-25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-26	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
25-07-28	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
25-07-27	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25-06-25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
25-06-24	Celyad Oncology Announces Strategic Review	CI
25-04-02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-18	Celyad: share price soars on encouraging data
25-02-18	Celyad Oncology Announces the Publication of the Preclinical and Clinical Data of CYAD-211 Providing Proof-Of-Concept of Its miRNA-Based shRNA Platform	CI
24-09-17	Celyad Oncology Names New CEO to Start in October	MT

Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company